Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Ono Pharmaceutical Co., Ltd.    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD.

(4528)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials
Sales 2021 313 B 3 023 M 3 023 M
Net income 2021 71 705 M 692 M 692 M
Net cash position 2021 105 B 1 016 M 1 016 M
P/E ratio 2021 21,7x
Yield 2021 1,57%
Sales 2022 356 B 3 439 M 3 439 M
Net income 2022 86 993 M 839 M 839 M
Net cash position 2022 148 B 1 425 M 1 425 M
P/E ratio 2022 17,7x
Yield 2022 1,90%
Capitalization 1 551 B 14 968 M 14 962 M
EV / Sales 2021 4,61x
EV / Sales 2022 3,94x
Nbr of Employees 3 560
Free-Float 76,6%
More Financials
Company
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals. 
Sector
Pharmaceuticals
Calendar
02/01Earnings Release
More about the company
Notations Surperformance© of Ono Pharmaceutical Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about ONO PHARMACEUTICAL CO., LTD.
01/13ONO PHARMACEUTICAL : Notice on the Adopter of the 'Osamu Hayaishi Memorial Schol..
AQ
2020ONO PHARMACEUTICAL : Enters into Exclusive License Agreement with Chordia Therap..
AQ
2020ONO PHARMACEUTICAL : Submits Supplemental Application for Approval for Opdivo to..
AQ
2020BRISTOL MYERS SQUIBB : Ono Pharmaceutical - Combination Therapy concerning Opdiv..
AQ
2020ONO PHARMACEUTICAL : Receives Approval of BRAFTOVI Capsule, a BRAF Inhibitor and..
AQ
2020BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo as Secon..
AQ
2020ONO PHARMACEUTICAL : Selected for the First Time for DJSI World Index and DJSI A..
AQ
2020ONO PHARMACEUTICAL : FOIPAN Tablets, a Protease Enzyme Inhibitor, Started Clinic..
AQ
2020Licensing, ONO and Bristol Myers Squibb Enter Patent License Agreement with R..
AQ
2020ONO PHARMACEUTICAL : and BMSKK Submit Supplemental Applications for Opdivo and Y..
AQ
2020Ono and Takeda Submit Supplemental Application for Opdivo and CABOMETYX Combi..
AQ
2020Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMET..
AQ
2020RAFAEL : A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals Lead Compo..
AQ
2020SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenob..
AQ
2020Ono Enters into License Agreement on Cenobamate, an Antiepileptic Drug with S..
AQ
More news
News in other languages on ONO PHARMACEUTICAL CO., LTD.
2020ONO PHARMACEUTICAL CO., LTD. : Veröffentlichung des Jahresergebnisses
2020ONO PHARMACEUTICAL CO., LTD. : publication des résultats annuels
2020ONO PHARMACEUTICAL CO., LTD. : Veröffentlichung des Quartalsergebnisses
2020ONO PHARMACEUTICAL CO., LTD. : publication des résultats trimestriels
2019DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 18.07.2019 - 15.15 Uhr
More news
Chart ONO PHARMACEUTICAL CO., LTD.
Duration : Period :
Ono Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONO PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 3 577,27 JPY
Last Close Price 3 107,00 JPY
Spread / Highest target 35,2%
Spread / Average Target 15,1%
Spread / Lowest Target -6,66%
EPS Revisions
Managers and Directors
NameTitle
Gyo Sagara President & Representative Director
Toichi Takino Managing Executive Officer & GM-Research
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director & Executive Vice President
Isao Ono Director & Managing Executive Officer